BIVM-ERCC5

Across TCGA pan-cancer cohorts, BIVM-ERCC5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BIVM-ERCC5 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher BIVM-ERCC5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BIVM-ERCC5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

MESO, READ, and UCEC are the cancer types where BIVM-ERCC5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
READ	OS	Median	III,IV	0.328	0.751	.003	12	view →
UCEC	DFS	Median	All	0.961	0.624	.018	8	view →
COAD	DFS	Median	All	0.160	0.693	.020	6	view →
STAD	DFS	Median	All	0.211	0.709	.015	3	view →
BLCA	DFS	Median	III,IV	0.100	0.572	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BIVM-ERCC5–MESO (OS)

Open the MESO breakdown →